Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

Summary

This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.

During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.

No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.

Conditions

• Liver Cancer (Primary and Metastatic)
• Lung Cancer (Diagnosis)
• Bone Cancer Metastatic
• Bone Cancer Tumor
• Kidney Tumors
• Renal Cancer
• Hepatocellular Carcinoma (HCC)
• Renal Cell Carcinoma (Kidney Cancer)
• Renal Cell Carcinoma (RCC)
• Musculoskeletal Cancers
• Musculoskeletal Tumors
• Bone Tumors
• Lung Tumors

Sponsors & Collaborators

• European Commission

  collaborator OTHER

• Philips Medical Systems

  collaborator INDUSTRY

• Philips Electronics Nederland BV

  collaborator INDUSTRY

• Philips France Commercial

  collaborator INDUSTRY

• Philips GmbH Innovate Technologies

  collaborator UNKNOWN

• Quantum Surgical

  collaborator INDUSTRY

• IGEA

  collaborator INDUSTRY

• Hospices Civils de Lyon

  collaborator OTHER

• Assistance Publique - Hôpitaux de Paris

  collaborator OTHER

• EIBIR - European Institute for biomedical imaging research

  collaborator UNKNOWN

• Cardiovascular and Interventional Radiological Society of Europe

  collaborator OTHER

• Klinikum der Universität zu Köln, Institut für Klinische Chemie

  collaborator UNKNOWN

• Mark C Burgmans, MD PhD

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-07-01

Primary Completion

2030-12-31

Completion

2030-12-31

Countries

• France
• Netherlands

Study Locations